Resources for Healthcare Professionals (HCPs)
Speaker Bureau slides: The Importance of Considering Cardiovascular Health in Men with Prostate Cancer
Latest slide deck from Accord UK Speaker Bureau meeting series that took place in June 2025.
Read More
Speaker Bureau slides: HERO Study
Latest slide deck from Accord UK Speaker Bureau meeting series that took place in June 2025.
Read More
EAU 2025 Symposium Highlights Article
Symposium highlights published in the EMJ digital Journal of Urology following the Accord Symposium held during EAU congress 2025 in Madrid, Spain, 21-24 March 2025.
DownloadClinical Papers
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer – N.D. Shore, et al. (2020)
The HERO study was a multinational, randomised, open-label, Phase 3 trial to evaluate the efficacy and safety of ORGOVYX®, compared to leuprorelin, in men with advanced prostate cancer.1
Download
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network - A. Merseburger et al. (2024)
Provides insight and guidance to improving the management of CV risk in patients with prostate cancer undergoing ADT.7
Download
Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer – K.G Gaudian, et al. (2025)2
Gaudian, et al. explores patient-reported adherence to relugolix when combined with stereotactic body radiation therapy (SBRT) for intermediate to high-risk prostate cancer.9
Download
Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective - T. Buchler (2025)
Buchler evaluates the pharmacokinetics, efficacy, safety and interactions of the coadministration of ORGOVYX® with androgen receptor pathway inhibitors (ARPIs) for the treatment of advanced prostate cancer.10
Download
Buchler et al. (2025) Clinical Paper Summary
Download the slide deck summarising real-world data on relugolix co-administered with ARPIs in metastatic prostate cancer, based on Buchler 202510
Download
Cirne et al. (2022) Clinical Paper Summary
Download the slide deck summarising findings on cardiovascular risks of GnRH antagonists vs. agonists from the Cirne 2022 study11
Download
Merseberger et al. (2024) Clinical Paper Summary
Download the slide deck outlining expert recommendations on cardiovascular risk assessment and multidisciplinary care in ADT-treated prostate cancer, from Merseburger 20247
Download
Nelson et al. (2023) Clinical Paper Summary
Download the slide deck summarising Nelson et al. (2023) on the cardiovascular safety of GnRH antagonists versus agonists in prostate cancer12
Download
Shore et al. (2020) Clinical Paper Summary
Download the slide deck summarising the efficacy and safety of oral relugolix vs leuprorelin in men with advanced prostate cancer, based on Shore et al. (2020)1
Download
Weiner et al. (2021) Clinical Paper Summary
Download the slide deck summarising Weiner et al. (2021) on causes of death in US men with prostate cancer, stratified by stage and demographics13
DownloadResources for Patients
Please do not share this page directly with patients and instead download the resources for offline use to show or share during appointments.
The Unmentionables: Online Discussion Guide
Enables your patient to answer questions to help personalise their next appointment with their healthcare team.
Read More
The Unmentionables: Podcast
Podcast series hosted by Jeff Stelling helping people to talk openly about what matters most in prostate cancer. This podcast is for people diagnosed with prostate cancer and their families.
Read MoreORGOVYX® is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer; for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy; as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.8
ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; APMA, Asia Pacific Multidisciplinary Action; CV, cardiovascular; CVD; cardiovascular disease; ESC, European Society of Cardiology; ESMO, European Society for Medical Oncology; GnRH, gonadotropin-releasing hormone; HCP, healthcare professional; MCBS, magnitude of clinical benefit scale; NICE, National Institute for Health and Care Excellence; PCCV, Prostate Cancer Cardiovascular; SMC, Scottish Medicines Consortium; TA, technology appraisal.